Dimethyl fumarate
- Generic Name
- Dimethyl fumarate
- Brand Names
- Tecfidera, Skilarence, Dimethyl fumarate Neuraxpharm, Dimethyl fumarate Mylan, Dimethyl fumarate Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C6H8O4
- CAS Number
- 624-49-7
- Unique Ingredient Identifier
- FO2303MNI2
- Background
Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-...
- Indication
Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- Associated Conditions
- Clinically Isolated Syndrome (CIS), Relapsing Forms of MS, Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate
- Conditions
- Interventions
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Biogen
- Registration Number
- NCT02090348
Dimethyl Fumarate (DMF) Observational Study
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 5487
- Registration Number
- NCT02047097
- Locations
- 🇸🇰
Research site, Martin, Slovakia
🇨🇦Research Sites, Montreal, Quebec, Canada
🇬🇧Research Site, Swansea, United Kingdom
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
- Conditions
- Interventions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1114
- Registration Number
- NCT01930708
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
BG00012 Regional Absorption Study
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 32
- Registration Number
- NCT01924832
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Biogen Multiple Sclerosis Pregnancy Exposure Registry
- Conditions
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 408
- Registration Number
- NCT01911767
- Locations
- 🇬🇧
Research Site, Salford, Greater Manchester, United Kingdom
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 333
- Registration Number
- NCT01903291
- Locations
- 🇺🇸
Research Site, Neenah, Wisconsin, United States
An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
- Conditions
- Interventions
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 225
- Registration Number
- NCT01838668
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇵🇱Miedzyleski Szpital Specjalistyczny, Warszawa, Poland
🇵🇱Nzoz Novo-Med, Katowice, Poland
Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2013-03-21
- Last Posted Date
- 2016-08-09
- Lead Sponsor
- Forward-Pharma GmbH
- Registration Number
- NCT01815723
- Locations
- 🇨🇦
Probity Medical Research, Waterloo, Ontario, Canada
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2010-07-02
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 108
- Registration Number
- NCT01156311
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
- Conditions
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1736
- Registration Number
- NCT00835770
- Locations
- 🇬🇧
Research Site, Stoke on Trent, United Kingdom
🇺🇸research Site, Mesa, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.